Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Teva- Pharmaceutical Industries Ltd.
Nieuws
Teva- Pharmaceutical Industries Ltd.
TEVA
NYS
: TEVA
| ISIN: US8816242098
3/07/2025
17,01 USD
(-0,23%)
(-0,23%)
3/07/2025
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Technische analyse
TA
Toon enkel gratis nieuws
26 juni 2025 ·
Teva Releases Q2 2025 Aide Memoire
· Persbericht
25 juni 2025 ·
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
· Persbericht
24 juni 2025 ·
Les données définitives de l’étude PEARL menée par Teva en conditions réelles confirment l’efficacité à long terme d’AJOVY® (frémanézumab) pour la prévention de la migraine chronique et épisodique
· Persbericht
23 juni 2025 ·
Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine
· Persbericht
16 juni 2025 ·
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
· Persbericht
3 juni 2025 ·
Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
· Persbericht
3 juni 2025 ·
Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement
· Persbericht
31 mei 2025 ·
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
· Persbericht
31 mei 2025 ·
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date
· Persbericht
29 mei 2025 ·
Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
· Persbericht
27 mei 2025 ·
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
· Persbericht
27 mei 2025 ·
Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
· Persbericht
27 mei 2025 ·
Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
· Persbericht
22 mei 2025 ·
Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
· Persbericht
20 mei 2025 ·
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
· Persbericht
20 mei 2025 ·
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
· Persbericht
19 mei 2025 ·
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
· Persbericht
19 mei 2025 ·
Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
· Persbericht
16 mei 2025 ·
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
· Persbericht
12 mei 2025 ·
Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe